Approval spans early and levodopa-treated disease; a 6-week titration and CYP3A interactions put pharmacists at the center of starting therapy.
|Articles|September 28, 2021
Pharmacy Clinical Pearl of the Day: Symptoms of Alzheimer Disease
Author(s)Saro Arakelians, PharmD
Approximately 5.8 million people in the United States 65 years of age and older live with Alzheimer disease.
Advertisement
Clinical Pearl of the Day: Symptoms of Alzheimer Disease
Alzheimer disease is a progressive neurologic disorder that causes the brain to shrink (atrophy) and brain cells to die.
Explanation:
- Alzheimer disease is the most common cause of dementia—a continuous decline in thinking, behavioral, and social skills that affects a person's ability to function independently.
- Approximately 5.8 million people in the United States 65 years of age and older live with Alzheimer disease.
- Symptoms include loss of memory and loss of appropriate thinking and reasoning process.
- Changes in the personality may include depression, social withdrawal, mood swings, distrust in others, irritability, wandering, and delusions.
- Causes may include beta-amyloid plaques and Tau protein tangles.
- Treatment may include Cholinesterase inhibitors, such as donepezil (Aricept), galantamine (Razadyne) and rivastigmine (Exelon), memantin (Namenda), and, most recently,
aducanumab (Aduhelm) .
Sources:
Advertisement
Related to this article
Imaging data from the CONTENTed study suggest the type 2 inflammation that drives severe asthma may affect more than the airways.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Pharmacists can help overcome influenza vaccine hesitancy by correcting common misconceptions, routinely asking every patient about vaccination, and leveraging their standing as trusted health care professionals.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1c reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
In a FINE-HEART analysis, cancer history raised the risk of death and hospitalization but did not blunt finerenone's cardiovascular and kidney benefits.
Hemoglobin, platelets, bleeding, pericardial effusions, and intrapulmonary shunting top the monitoring list for patients with pulmonary arterial hypertension (PAH) starting with sotatercept, according to Vallerie McLaughlin, MD.
Marie-Claire Seeley, PhD, MNurs, RN, discusses standing tests, medication review, and what inflammatory findings may mean for future POTS treatment.
Advertisement
Advertisement
Trending on Pharmacy Times
1
FDA Approves Tiratricol, First Treatment for MCT8 Deficiency
2
Intensive Chemotherapy in Combination With Quizartinib Versus Midostaurin for FLT3-ITD Mutated Acute Myeloid Leukemia: A Multicenter Cohort Study
3
Retatrutide Cuts Weight Up to 18.8% in Adults With T2D, Obesity
4
Pharmacists Can Close CKD Medication Adherence Gaps, PHTI Says
5